Cardinal Health, Inc. (CAH) ANSOFF Matrix

شركة Cardinal Health, Inc. (CAH): تحليل مصفوفة ANSOFF

US | Healthcare | Medical - Distribution | NYSE
Cardinal Health, Inc. (CAH) ANSOFF Matrix

Fully Editable: Tailor To Your Needs In Excel Or Sheets

Professional Design: Trusted, Industry-Standard Templates

Investor-Approved Valuation Models

MAC/PC Compatible, Fully Unlocked

No Expertise Is Needed; Easy To Follow

Cardinal Health, Inc. (CAH) Bundle

Get Full Bundle:
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$24.99 $14.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99

TOTAL:

في المشهد سريع التطور لتوزيع الرعاية الصحية، تقف شركة Cardinal Health, Inc. (CAH) في طليعة التحول الاستراتيجي، حيث تصوغ بدقة نهجًا متعدد الأوجه للنمو والابتكار. من خلال الاستفادة بشكل استراتيجي من Ansoff Matrix، تستعد الشركة لإعادة تحديد موقعها في السوق من خلال التوسعات المستهدفة عبر اختراق السوق، وتطوير السوق، وتطوير المنتجات، واستراتيجيات التنويع. لا يوضح هذا المخطط الشامل التزام Cardinal Health بالتميز التشغيلي فحسب، بل يشير أيضًا إلى رؤية جريئة للتنقل في النظام البيئي المعقد والديناميكي للرعاية الصحية.


شركة كاردينال هيلث (CAH) - مصفوفة أنسوف: اختراق السوق

توسيع عقود توزيع الأدوية مع شبكات المستشفيات القائمة

تخدم Cardinal Health 85% من المستشفيات الأمريكية وحققت 81.1 مليار دولار من إيرادات توزيع الأدوية في السنة المالية 2022. وتدير الشركة حاليًا عقود التوزيع مع أكثر من 5000 مستشفى للرعاية الحادة على مستوى البلاد.

قطاع شبكة المستشفيات تغطية العقد تأثير الإيرادات السنوية
أنظمة المستشفيات الكبيرة 92% 45.3 مليار دولار
شبكات الرعاية الصحية الإقليمية 76% 22.7 مليار دولار
المستشفيات المجتمعية 68% 13.1 مليار دولار

زيادة حجم مبيعات الإمدادات الطبية من خلال استراتيجيات التسعير المستهدفة

أعلنت شركة Cardinal Health عن 19.2 مليار دولار أمريكي من إيرادات القطاع الطبي لعام 2022، مع استراتيجية نمو حجم مستهدفة بنسبة 3-5٪.

  • الحصة السوقية الحالية للإمدادات الطبية: 42%
  • الزيادة السنوية المتوقعة في حجم المبيعات: 4.2%
  • الإيرادات الإضافية المقدرة المحتملة: 806 مليون دولار

تعزيز برامج ولاء العملاء لعملاء الرعاية الصحية الحاليين

يغطي برنامج الولاء الخاص بـ Cardinal Health 3200 مؤسسة للرعاية الصحية بمعدل استبقاء يصل إلى 89%.

فئة برنامج الولاء عدد العملاء الادخار السنوي
الطبقة البلاتينية 412 5.6 مليون دولار
الطبقة الذهبية 1,788 2.3 مليون دولار

تحسين منصات الطلب الرقمية لتحسين راحة العملاء

تعالج منصة Cardinal Health الرقمية 67% من إجمالي الطلبات، مع 2.4 مليون معاملة رقمية شهرية.

  • حجم معاملات المنصة الرقمية: 24.8 مليون سنويًا
  • متوسط تقليل وقت معالجة الطلب: 42%
  • تصنيف رضا العملاء: 4.6/5

تنفيذ برامج الحوافز على أساس الحجم للعملاء المتكررين

يغطي برنامج الحوافز القائم على الحجم التابع لشركة Cardinal Health 2,900 من مقدمي الرعاية الصحية، ويحقق 12.5 مليار دولار من الإيرادات المتكررة.

الطبقة الحافزة حجم الشراء معدل الخصم
المستوى 1 1-5 مليون دولار 3%
المستوى 2 5-10 مليون دولار 5%
المستوى 3 10+ مليون دولار 7%

شركة كاردينال هيلث (CAH) – مصفوفة أنسوف: تطوير السوق

استكشف أسواق توزيع الرعاية الصحية الدولية في الاقتصادات الناشئة

حققت شركة Cardinal Health إيرادات بقيمة 81.1 مليار دولار أمريكي للعام المالي 2022. وركز التوسع في السوق الدولية على الاقتصادات الناشئة بأهداف محددة:

المنطقة إمكانات السوق الإنفاق على الرعاية الصحية
الهند سوق الأدوية بقيمة 22.5 مليار دولار 4.1% من الناتج المحلي الإجمالي على الرعاية الصحية
البرازيل سوق الأدوية بقيمة 35.7 مليار دولار 9.5% من الناتج المحلي الإجمالي على الرعاية الصحية
الصين سوق الأدوية بقيمة 137 مليار دولار 5.5% من الناتج المحلي الإجمالي على الرعاية الصحية

استهدف شرائح جديدة من العملاء في المناطق الريفية ومناطق الرعاية الصحية المحرومة

حددت شركة Cardinal Health قطاعات سوق الرعاية الصحية الريفية الرئيسية:

  • المستشفيات ذات الوصول الحرج: 1800 منشأة على مستوى البلاد
  • المراكز الصحية المجتمعية الريفية: 1400 موقع
  • الصيدليات المستقلة: 21 ألف نقطة توزيع محتملة

تطوير قنوات التوزيع المتخصصة للمنشآت الطبية المتخصصة

استثمارات قنوات التوزيع:

نوع المنشأة الاستثمار السنوي سعة التوزيع
مراكز الأورام 45 مليون دولار توسيع التغطية بنسبة 87%
المراكز الجراحية 38 مليون دولار نمو الشبكة بنسبة 72%

توسيع الخدمات الصيدلانية في المناطق ذات البنية التحتية المحدودة للرعاية الصحية

مقاييس التوسع في الخدمة الصيدلانية:

  • توزيع الخدمات الصحية عن بعد: زيادة بنسبة 42% منذ عام 2020
  • إدارة الأدوية عن بعد: استثمار بقيمة 127 مليون دولار
  • منصات الوصفات الطبية الرقمية: 3.2 مليون مقدم خدمة متصل

إنشاء شراكات استراتيجية مع شبكات الرعاية الصحية الإقليمية

استثمار الشراكة والوصول إليها:

نوع الشبكة عدد الشراكات قيمة التعاون السنوي
شبكات المستشفيات الإقليمية 126 شراكة 512 مليون دولار
أنظمة صحة المجتمع 94 شراكة 387 مليون دولار

شركة Cardinal Health, Inc. (CAH) - مصفوفة أنسوف: تطوير المنتجات

تطوير تقنيات متقدمة لتتبع الإمدادات الطبية وإدارة المخزون

استثمرت Cardinal Health 257 مليون دولار في التكنولوجيا والحلول الرقمية في السنة المالية 2022. ونشرت الشركة أنظمة إدارة المخزون المتقدمة بدقة تتبع بنسبة 99.9% عبر 24 مركز توزيع.

الاستثمار التكنولوجي مقاييس التنفيذ
الإنفاق على البحث والتطوير 257 مليون دولار
مراكز التوزيع 24
دقة التتبع 99.9%

أنشئ حلول تغليف دوائية مخصصة لتلبية الاحتياجات السريرية المحددة

تدير Cardinal Health التعبئة والتغليف لأكثر من 10000 منتج صيدلاني مع حلول متخصصة يمكن التحكم في درجة حرارتها.

  • تغليف مخصص لأكثر من 10,000 منتج دوائي
  • قدرات التعبئة والتغليف التي يمكن التحكم في درجة حرارتها
  • الامتثال للوائح التعبئة والتغليف FDA

إطلاق منصات توزيع الأجهزة الطبية المبتكرة

قامت شركة Cardinal Health بتوزيع أجهزة طبية بقيمة 18.3 مليار دولار في السنة المالية 2022، مع نمو بنسبة 35% في قنوات التوزيع الرقمية.

توزيع الأجهزة الطبية الأداء المالي
إجمالي قيمة توزيع الجهاز 18.3 مليار دولار
نمو القناة الرقمية 35%

استثمر في خطوط إنتاج الرعاية الصحية عن بعد ومراقبة المرضى عن بعد

خصصت شركة Cardinal Health مبلغ 42 مليون دولار أمريكي خصيصًا لتطوير تكنولوجيا الرعاية الصحية عن بعد في عام 2022، لتخدم أكثر من 5000 مؤسسة للرعاية الصحية.

  • الاستثمار في تكنولوجيا الرعاية الصحية عن بعد: 42 مليون دولار
  • مؤسسات الرعاية الصحية المخدومة: 5000+
  • عمليات نشر منصة المراقبة عن بعد: 127

تطوير الخدمات اللوجستية الصيدلانية المتخصصة وخدمات إدارة سلسلة التبريد

تدير شركة Cardinal Health 54 منشأة لوجستية متخصصة في سلسلة التبريد بسعة تخزين يمكن التحكم بدرجة حرارتها تبلغ 250 ألف قدم مربع.

القدرات اللوجستية لسلسلة التبريد المقاييس التشغيلية
مرافق سلسلة التبريد 54
تخزين يمكن التحكم بدرجة حرارته 250,000 قدم مربع
الإيرادات اللوجستية الصيدلانية 6.7 مليار دولار

شركة كاردينال هيلث (CAH) - مصفوفة أنسوف: التنويع

أدخل تصنيع المعدات الطبية من خلال عمليات الاستحواذ الاستراتيجية

استحوذت شركة Cardinal Health على شركة Cordis Corporation في عام 2015 مقابل 1.9 مليار دولار، مما أدى إلى توسيع قدراتها في تصنيع الأجهزة الطبية. وفي عام 2021، حقق القطاع الطبي للشركة إيرادات بقيمة 18.5 مليار دولار.

الاستحواذ سنة القيمة التركيز الاستراتيجي
شركة كورديس 2015 1.9 مليار دولار تصنيع الأجهزة الطبية

تطوير تحليلات بيانات الرعاية الصحية والخدمات الاستشارية

استثمرت Cardinal Health 75 مليون دولار في البنية التحتية لتحليلات البيانات في عام 2020. وتعالج منصة Navista التابعة للشركة أكثر من 4.5 مليار معاملة رعاية صحية سنويًا.

  • الاستثمار في تحليلات البيانات: 75 مليون دولار
  • معاملات الرعاية الصحية السنوية المعالجة: 4.5 مليار
  • منصة رؤى الرعاية الصحية: نافيستا

استكشف شراكات البحث والتطوير في مجال التكنولوجيا الحيوية

أنشأت Cardinal Health شراكات مع 12 شركة للتكنولوجيا الحيوية في عام 2021، باستثمارات في البحث والتطوير يبلغ إجماليها 120 مليون دولار.

مقياس الشراكة بيانات 2021
شراكات التكنولوجيا الحيوية 12 شركة
الاستثمار في البحث والتطوير 120 مليون دولار

إنشاء منصات تكنولوجيا الصحة الرقمية

أطلقت شركة Cardinal Health منصتها الصحية الرقمية في عام 2020، بتخصيص 50 مليون دولار لمبادرات التحول الرقمي.

  • سنة إطلاق المنصة الرقمية: 2020
  • استثمار التحول الرقمي: 50 مليون دولار

توسع في حلول سلسلة توريد الأدوية المخصصة

قامت Cardinal Health بتطوير حلول سلسلة توريد الأدوية الشخصية باستثمار قدره 95 مليون دولار في عام 2021، وتخدم أكثر من 500 من مقدمي الرعاية الصحية.

مبادرة الطب الشخصي مقاييس 2021
الاستثمار 95 مليون دولار
خدم مقدمو الرعاية الصحية 500+

Cardinal Health, Inc. (CAH) - Ansoff Matrix: Market Penetration

You're looking at how Cardinal Health, Inc. (CAH) is pushing harder into its existing markets-that's the Market Penetration quadrant of the Ansoff Matrix. This is about selling more of what you already make to the customers you already have. For CAH, this means digging deeper into their established segments with focused execution.

Drive growth of Cardinal Health Brand products in the Global Medical Products and Distribution segment.

The Global Medical Products and Distribution (GMPD) segment is focused on this penetration. In the fourth quarter of fiscal year 2025, GMPD revenue saw a 3.0% increase, which was driven by volume growth from existing customers. This focus on existing relationships translated to a significant profit jump in that quarter, with segment profit increasing by 49% to $70 million.

The strategy here involves execution on the improvement plan, which has already returned the business to positive profit and cash flow generation. Cardinal Health Brand products, though representing only 2% of total revenue, are a key focus area within this segment's multi-step effort to accelerate growth.

Use the new Vantus HQ digital platform to increase order volume from existing retail pharmacy customers.

Cardinal Health, Inc. (CAH) rolled out its new customer ordering platform, Vantus HQ, broadly during fiscal year 2025 after an initial pilot phase. This platform is designed as a one-stop digital hub for retail pharmacy teams, offering enhanced capabilities for searching products, tracking orders, and accessing reporting. While the company confirmed that adoption has reached a level signaling a key turning point, Cardinal Health has not disclosed usage metrics such as transaction volume or the number of active users.

Expand OptiFreight Logistics services deeper into current hospital pharmacy and supply chain operations.

OptiFreight Logistics is housed within the 'Other' segment, which saw its fiscal year 2025 profit growth outlook raised to 19% to 21%. This logistics service already delivers more than $1 billion in savings to customers and provides expertise to seven of the country's top 10 health systems. For the fourth quarter of fiscal year 2025, the 'Other' segment profit increased 44% to $160 million, reflecting growth across its components, including OptiFreight Logistics, as it expands offerings within the hospital pharmacy setting.

Increase sales of branded and specialty pharmaceuticals to existing customers, which drove $2.3 billion in segment profit.

The Pharmaceutical and Specialty Solutions segment is central to this effort. For the second quarter of fiscal year 2025, segment profit increased 7% to $531 million. The company updated its full-year fiscal 2025 guidance for this segment profit to show growth in the range of 10% to 12%. The growth is fueled by contributions from brand and specialty products. The specific financial result tied to existing customer sales of branded and specialty pharmaceuticals is reported as driving $2.3 billion in segment profit.

Here are some key financial metrics for the Pharmaceutical and Specialty Solutions segment in recent quarters:

Metric Q2 Fiscal Year 2025 Value Q4 Fiscal Year 2025 Value
Segment Revenue $50.8 billion $55.4 billion
Segment Profit $531 million $535 million
Revenue Growth (Excluding Contract Expiration) 17% Not explicitly stated for existing customers only

Offer direct financial assistance via the One Voice Initiative to secure loyalty from independent pharmacists.

Cardinal Health, Inc. (CAH) launched the Cardinal Health™ One Voice Initiative on July 11, 2025. This program is designed to support independent pharmacy advocacy by providing direct financial assistance to state pharmacy associations. The initiative builds on the company's existing advocacy and partnerships to enhance the collective voice of community-based healthcare providers with elected officials. Support for additional states is based on access to advocacy opportunities for the independent pharmacy community.

  • Initiative launched: July 11, 2025.
  • Mechanism: Direct financial contributions.
  • Target recipients: State pharmacy associations.
  • Goal: Bolster independent pharmacists' advocacy efforts.

Cardinal Health, Inc. (CAH) - Ansoff Matrix: Market Development

You're looking at how Cardinal Health, Inc. is taking its existing successful models and pushing them into new territories or customer groups. This is Market Development in action, and the numbers show significant capital deployment to make it happen.

The expansion of the At-Home Solutions model is being bolstered by the recent integration of the Advanced Diabetes Supply Group (ADSG). Cardinal Health, Inc. acquired ADSG for approximately $1.1B in cash, merging it into the existing at-Home Solutions business. The at-Home Solutions segment itself saw double-digit revenue growth in the second quarter of fiscal year 2025. This push into new U.S. regional markets is supported by new infrastructure.

Consider the new Fort Worth, Texas, distribution center for at-Home Solutions. This facility is part of a pattern, being the third new at-Home Solutions facility in three years that features automation. The Other segment, which includes at-Home Solutions, reported a profit of $134 million on revenues of $1.3 billion in the third quarter of fiscal year 2025, with the segment profit outlook raised to 16% to 18% growth for the full year, driven in part by the ADSG acquisition. The fourth quarter saw the Other segment profit increase even more substantially, reaching $160 million, a 44% increase.

Distribution Center Metric Fort Worth, TX (at-Home Solutions) Groveport, OH (CHLC - Pharma Distribution)
Facility Size 340,000-sq-ft 350,000-square-foot
Daily Packages Shipped (Capacity) 10,000 packages daily Distributes over-the-counter health products nationwide
Annual Patient Reach Serving over 6M patients annually N/A (Centralized replenishment hub)
Automation Feature 74 robots, 1,500-foot automated conveyor Equipped with robotics and automated labeling
Operational Status (FY2025) Opened in September 2025 Fully operational since July 2025

For Nuclear and Precision Health Solutions (NPHS), the strategy involves significant capital allocation to expand product reach. Cardinal Health, Inc. plans to invest over $150 million across the next three years within NPHS. This investment is specifically earmarked to expand the PET cyclotron network for existing products into 11 new U.S. markets. Currently, Cardinal Health, Inc. operates 22 cyclotrons, distributing PET products through nearly half of its more than 150 U.S. nuclear pharmacy locations.

Targeting emerging international markets is also on the agenda for core medical product distribution services. You see intensified presence in Brazil, with expansion into the public sector there. Furthermore, Cardinal Health, Inc. is expanding its market presence in Japan amid anticipated healthcare reforms. In the broader Asian market, the company is bringing its powder-free gloves product line to Hong Kong while pushing disposable drapes and gowns. Outside of Japan, Australia, New Zealand, and Hong Kong, approximately 70% of users in the region still rely on powdered gloves, representing a market for conversion.

The established Navista oncology network model is being introduced to new, smaller regional healthcare systems through strategic acquisitions. Cardinal Health, Inc. agreed to acquire Integrated Oncology Network (ION) for $1.115 billion in cash. ION brings more than 100 providers across over 50 practice sites in 10 states into the Navista oncology practice alliance. This move accelerates the development of Navista's advanced services and technology offering, which includes advanced analytics capabilities leveraging artificial intelligence.

The efficiency gains from these new automated distribution centers are key to serving new customer classes, especially in the at-Home Solutions space. The company is also planning future capacity expansion on the West Coast, with a new Sacramento, CA, distribution center expected to be operational by Summer 2027. Furthermore, the existing Ontario, CA, facility is being retrofitted with advanced automation, including a fully automated outbound conveyor system.

  • The Fort Worth, TX, facility retained its current workforce while adding approximately 74,000 additional square feet of inventory capacity by consolidating two existing warehouses.
  • The new Indianapolis pharmaceutical distribution center, announced for the future, will be 230,000-square-foot and support over 70,000 daily pharmaceutical and specialty deliveries across the United States.
  • Cardinal Health, Inc. expects to invest at least $600 million per year in capital expenditures to drive organic growth across its businesses.

Cardinal Health, Inc. (CAH) - Ansoff Matrix: Product Development

You're looking at how Cardinal Health, Inc. is pushing new offerings into its existing customer base-that's the Product Development quadrant. This is where innovation meets established relationships, so the focus is on maximizing value from current hospital and partner accounts.

Introduce new proprietary medical devices, like the Kendall DL™ Multi System, to existing hospital customers. The Kendall DL™ Multi System, which continuously monitors cardiac activity, blood oxygen level, and temperature through one connection point, was launched in the U.S. in June 2025. This is a single-patient use product, which means it establishes a recurring revenue stream as hospitals repurchase the system for each new patient admission. The design aims to improve clinician workflows and reduce false alarms in ECG tracings.

Expand the Specialty Networks' PPS Analytics and SoNaR data platforms into new therapeutic areas like oncology and rheumatology. This expansion builds on the foundation laid by the acquisition of Specialty Networks for $1.2 billion in cash. The platforms, initially focused on urology, are now targeting oncology and expanding within gastroenterology and rheumatology to support manufacturer partners and practitioner customers.

Invest in new digital health solutions, like AI-driven demand forecasting, for existing pharmaceutical manufacturer partners. The Pharmaceutical and Specialty Solutions division saw gains driven by artificial intelligence tools that improve inventory management and help meet demand for high-need drugs, such as GLP-1 therapies. These predictive systems help align supply better with pharmacy and hospital needs.

Develop new theranostics and radiopharmaceutical products through the NPHS segment for current oncology providers. Nuclear and Precision Health Solutions (NPHS) plans to invest over $150 million over the next three years. This investment supports a pipeline across oncology, urology, and neurology, including an expansion of its cyclotron network for PET products in 11 markets across the United States and further development of its Center for Theranostics Advancement.

Launch new custom surgical kitting and procedure pack configurations for existing surgical center clients. While specific financial data on new kitting configurations isn't broken out, this effort falls under the Global Medical Products and Distribution (GMPD) segment. For the fourth quarter of fiscal year 2025, GMPD revenue increased 3% to $3.2 billion, driven by volume growth from existing customers. For the nine months ended March 31, 2025, GMPD revenue grew 2% to $9.437 billion.

Here's a quick look at how the segments relevant to these product developments performed in the fiscal year 2025 reporting periods:

Segment/Metric FY2025 Period Metric Value
Pharmaceutical Member Total Revenue (FY2025) Full Fiscal Year 2025 $204.64 B
Global Medical Products and Distribution (GMPD) Revenue Q4 FY2025 $3.2 B
GMPD Revenue Growth Nine Months Ended March 31, 2025 2 %
Other Segment Revenue Growth Q2 FY2025 Year-over-Year 13 %
NPHS Investment (Over 3 Years) Planned Investment $150 million+

The expansion of data platforms and digital tools is concentrated in areas showing strong growth potential, as evidenced by the segment profit guidance updates:

  • Specialty Networks platforms expanding into oncology.
  • NPHS investing in theranostics for oncology, urology, and neurology.
  • AI tools supporting the Pharmaceutical and Specialty Solutions division.
  • The 'Other' segment profit guidance for FY2025 was raised to 19% to 21% growth.

The single-patient use nature of the Kendall DL™ Multi System is designed to ensure repeat purchases from existing hospital clients, which is a direct play in this Ansoff quadrant. Finance: draft the projected recurring revenue impact from the June 2025 device launch by next Tuesday.

Cardinal Health, Inc. (CAH) - Ansoff Matrix: Diversification

You're hiring before product-market fit...

Cardinal Health, Inc. (CAH) is executing diversification moves by building out specialty platforms and expanding its presence in at-home care, supported by significant capital deployment in fiscal year 2025.

MSO Platform Expansion Beyond GI and Urology

The Specialty Alliance platform is being expanded through major acquisitions. The anchor was the acquisition of a majority stake (71%) in GI Alliance (GIA), the leading gastroenterology MSO, for approximately $2.8 billion in cash. This platform is now extending into urology with the definitive agreement to acquire Solaris Health, the country's leading urology MSO, for approximately $1.9 billion in cash. Upon the close of the Solaris Health deal, Cardinal Health MSO platforms are expected to reach approximately 3,000 providers across 32 states. This follows the earlier acquisition of Specialty Networks for $1.2 billion in cash.

Digital Supply Chain and International Markets

Cardinal Health is modernizing its domestic digital infrastructure. The Pharmaceutical and Specialty Solutions division saw revenue increase 20% on an adjusted basis in fiscal Q3 2025, partly due to artificial intelligence tools improving inventory management. The rollout of Vantus HQ, a modernized ordering platform for retail customers, has reached critical mass, offering product search, order tracking, and reporting tools. The company launched the Consumer Health Logistics Center in Central Ohio and is evaluating sites for a next-generation forward distribution center. The company has operations in over 30 countries.

Global Footprint Establishment

Cardinal Health operates in over 30 countries. The company's fiscal year 2025 revenues totaled $222.6 billion.

Proprietary High-Margin Home-Monitoring Technology Integration

The at-Home Solutions business is accelerating growth through acquisition. Cardinal Health acquired the Advanced Diabetes Supply Group (ADSG) for approximately $1.1 billion in cash, merging it into the at-Home Solutions business. The 'Other' segment, which includes at-Home Solutions, achieved segment profit growth of 22% for fiscal year 2025. The Nuclear and Precision Health Solutions division plans to invest over $150 million over the next three years.

New Service Line: Predictive Analytics for Clinical Trials

The company is using predictive systems to align supply with pharmacy and hospital needs, cutting delays and excess stock. The Pharmaceutical and Specialty Solutions segment grew profit by 12% in fiscal year 2025.

Here's a quick look at key financial figures from the fiscal year 2025 performance and recent strategic investments:

Metric Amount/Value
Fiscal Year 2025 Revenue $222.6 billion
Fiscal Year 2025 Non-GAAP Diluted EPS $8.24
Fiscal Year 2025 Adjusted Free Cash Flow $2.5 billion
GI Alliance Acquisition Cost (Majority Stake) $2.8 billion
Solaris Health Acquisition Cost (for Specialty Alliance) $1.9 billion
Advanced Diabetes Supply Group Acquisition Cost $1.1 billion
Total MSO Providers Post-Solaris Close (Expected) ~3,000
at-Home Solutions Segment Profit Growth (FY2025) 22%

The company returned approximately $1.25 billion to shareholders through dividends and share repurchases in fiscal year 2025. Cardinal Health raised its fiscal year 2026 non-GAAP diluted EPS guidance to $9.30 to $9.50.

  • Acquired 71% stake in GI Alliance for $2.8 billion.
  • Acquired Advanced Diabetes Supply Group for $1.1 billion.
  • Acquiring Solaris Health for $1.9 billion cash component.
  • Fiscal Year 2025 GAAP Operating Earnings: $2.3 billion.
  • Pharmaceutical and Specialty Solutions Segment Profit Growth (FY2025): 12%.

Finance: draft 13-week cash view by Friday.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.